Molecular biology of Huntington's disease

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 25-81

  Mcfarland, Karen N ^a   Cha, Jang Ho J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE PROTEIN;

ANIMAL; BOOK; DISEASE MODEL; GENETICS; HISTORY; HUMAN; HUNTINGTON CHOREA; MOLECULAR BIOLOGY; TRINUCLEOTIDE REPEAT;

ANIMALS; DISEASE MODELS, ANIMAL; HISTORY, 19TH CENTURY; HUMANS; HUNTINGTON DISEASE; MOLECULAR BIOLOGY; NERVE TISSUE PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 79954522923     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00003-3     Document Type: Book

References (496)

1. Acevedo-Torres K., Berrios L., Rosario N., et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst) 2009, 8:126-136.
2. Adamec E., Mohan P., Vonsattel J.P., et al. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol (Berl) 2002, 104:92-104.
3. Alonso M.E., Yescas P., Rasmussen A., et al. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Clin Genet 2002, 61:437-442.
4. Ambrose C., James M., Barnes G., et al. A novel G protein-coupled receptor kinase gene cloned from 4p16.3. Hum Mol Genet 1992, 1:697-703.
5. Ambrose C.M., Duyao M.P., Barnes G., et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994, 20:27-38.
6. Anborgh P.H., Godin C., Pampillo M., et al. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J Biol Chem 2005, 280:34840-34848.
7. Anderson K.D., Panayotatos N., Corcoran T.L., et al. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci USA 1996, 93:7346-7351.
8. Andrade M.A., Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet 1995, 11:115-116.
9. Andrade M.A., Petosa C., O'Donoghue S.I., et al. Comparison of ARM and HEAT protein repeats. J Mol Biol 2001, 309:1-18.
10. Andreassen O.A., Dedeoglu A., Ferrante R.J., et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001, 8:479-491.
11. Andresen J.M., Gayan J., Djousse L., et al. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet 2007, 71:295-301.
12. Andrich J., Saft C., Arz A., et al. Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD. Mov Disord 2004, 19:226-228.
13. Andrich J., Arning L., Wieczorek S., et al. Huntington's disease as caused by 34 CAG repeats. Mov Disord 2008, 23:879-881.
14. Anne S.L., Saudou F., Humbert S. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci 2007, 27:7318-7328.
15. Apostol B.L., Kazantsev A., Raffioni S., et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A 2003, 100:5950-5955.
16. Arning L., Monte D., Hansen W., et al. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med 2008, 86:485-490.
17. Aronin N., Chase K., Young C., et al. CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. Neuron 1995, 15:1193-1201.
18. Atwal R.S., Xia J., Pinchev D., et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007, 16:2600-2615.
19. Auerbach W., Hurlbert M.S., Hilditch-Maguire P., et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 2001, 10:2515-2523.
20. Babajko S., Petit S., Fernandes I., et al. Msx1 expression regulation by its own antisense RNA: consequence on tooth development and bone regeneration. Cells Tissues Organs 2009, 189:115-121.
21. Bae B.I., Xu H., Igarashi S., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47:29-41.
22. Banfi S., Servadio A., Chung M.Y., et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 1994, 7:513-520.
23. Bao J., Sharp A.H., Wagster M.V., et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A 1996, 93:5037-5042.
24. Baquet Z.C., Gorski J.A., Jones K.R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004, 24:4250-4258.
25. Barnes G.T., Duyao M.P., Ambrose C.M., et al. Mouse Huntington's disease gene homolog (Hdh). Somat Cell Mol Genet 1994, 20:87-97.
26. Bates E.A., Victor M., Jones A.K., et al. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci 2006, 26:2830-2838.
27. Bates G.P., MacDonald M.E., Baxendale S., et al. A yeast artificial chromosome telomere clone spanning a possible location of the Huntington disease gene. Am J Hum Genet 1990, 46:762-775.
28. Baxendale S., Abdulla S., Elgar G., et al. Comparative sequence analysis of the human and pufferfish Huntington's disease genes. Nat Genet 1995, 10:67-75.
29. Beal M.F., Kowall N.W., Ellison D.W., et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
30. Beal M.F., Brouillet E., Jenkins B., et al. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993, 61:1147-1150.
31. Beal M.F., Brouillet E., Jenkins B.G., et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13:4181-4192.
32. Beister A., Kraus P., Kuhn W., et al. The N-methyl-d-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004, 117-122.
33. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
34. Benn C.L., Landles C., Li H., et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet 2005, 14:3065-3078.
35. Benn C.L., Sun T., Sadri-Vakili G., et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008, 28:10720-10733.
36. Bennett E.J., Bence N.F., Jayakumar R., et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 2005, 17:351-365.
37. Bennett E.J., Shaler T.A., Woodman B., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
38. Bessert D.A., Gutridge K.L., Dunbar J.C., et al. The identification of a functional nuclear localization signal in the Huntington disease protein. Brain Res Mol Brain Res 1995, 33:165-173.
39. Bett J.S., Goellner G.M., Woodman B., et al. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 2006, 15:33-44.
40. Bhide P.G., Day M., Sapp E., et al. Expression of normal and mutant huntingtin in the developing brain. J Neurosci 1996, 16:5523-5535.
41. Bizat N., Hermel J.M., Boyer F., et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 2003, 23:5020-5030.
42. Bocharova N.A., Sokolov S.S., Knorre D.A., et al. Unexpected link between anaphase promoting complex and the toxicity of expanded polyglutamines expressed in yeast. Cell Cycle 2008, 7:3943-3946.
43. Bocharova N., Chave-Cox R., Sokolov S., et al. Protein aggregation and neurodegeneration: clues from a Yeast model of Huntington's disease. Biochemistry (Mosc) 2009, 74:231-234.
44. Borlongan C.V., Koutouzis T.K., Randall T.S., et al. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res Bull 1995, 36:549-556.
45. Boutell J.M., Wood J.D., Harper P.S., et al. Huntingtin interacts with cystathionine beta-synthase. Hum Mol Genet 1998, 7:371-378.
46. Boutell J.M., Thomas P., Neal J.W., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999, 8:1647-1655.
47. Bozza A., Malagu S., Calzolari E., et al. Expansion of a (CAG)n repeat region in a sporadic case of HD. Acta Neurol Scand 1995, 92:132-134.
48. Brennan W.A., Bird E.D., Aprille J.R. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985, 44:1948-1950.
49. Brook J.D., McCurrach M.E., Harley H.G., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808.
50. Brouillet E., Jenkins B.G., Hyman B.T., et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993, 60:356-359.
51. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006, 8:2061-2073.
52. Browne S.E., Bowling A.C., MacGarvey U., et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997, 41:646-653.
53. Brown T.B., Bogush A.I., Ehrlich M.E. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet 2008, 17:3095-3104.
54. Buckler A.J., Chang D.D., Graw S.L., et al. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc Natl Acad Sci U S A 1991, 88:4005-4009.
55. Burke J.R., Enghild J.J., Martin M.E., et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996, 2:347-350.
56. Butterworth J., Yates C.M., Reynolds G.P. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 1985, 67:161-171.
57. Callahan J.L., Andrews K.J., Zakian V.A., et al. Mutations in yeast replication proteins that increase CAG/CTG expansions also increase repeat fragility. Mol Cell Biol 2003, 23:7849-7860.
58. Cattaneo E., Conti L. Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J Neurosci Res 1998, 53:223-234.
59. Cha J.H. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007, 83:228-248.
60. Cha J.H., Kosinski C.M., Kerner J.A., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998, 95:6480-6485.
61. Charollais J., Van Der Goot F.G. Palmitoylation of membrane proteins. Mol Membr Biol 2008, 11:1-12.
62. Cho D.H., Thienes C.P., Mahoney S.E., et al. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 2005, 20:483-489.
63. Chun W., Lesort M., Tucholski J., et al. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol Dis 2001, 8:391-404.
64. Coles R., Leggo J., Rubinsztein D.C. Analysis of the 5' upstream sequence of the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the age at onset of HD. J Med Genet 1997, 34:371-374.
65. Coles R., Caswell R., Rubinsztein D.C. Functional analysis of the Huntington's disease (HD) gene promoter. Hum Mol Genet 1998, 7:791-800.
66. Coles R., Birdsall M., Wyttenbach A., et al. 12-O-tetradecanoyl-phorbol-13-acetate down-regulates the Huntingtin promoter at Sp1 sites. Neuroreport 2000, 11:3157-3161.
67. Colin E., Zala D., Liot G., et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. Embo J 2008, 27:2124-2134.
68. Cooper J.K., Schilling G., Peters M.F., et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998, 7:783-790.
69. Cornett J., Cao F., Wang C.E., et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005, 37:198-204.
70. David G., Abbas N., Stevanin G., et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997, 17:65-70.
71. Davies S.W., Turmaine M., Cozens B.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
72. de Almeida L.P., Ross C.A., Zala D., et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002, 22:3473-3483.
73. de Pril R., Fischer D.F., Roos R.A., et al. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Mol Cell Neurosci 2007, 34:10-19.
74. De Rooij K.E., De Koning Gans P.A., Skraastad M.I., et al. Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. J Med Genet 1993, 30:996-1002.
75. Diaz-Hernandez M., Hernandez F., Martin-Aparicio E., et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003, 23:11653-11661.
76. Diekmann H., Anichtchik O., Fleming A., et al. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J Neurosci 2009, 29:1343-1349.
77. Dietrich P., Shanmugasundaram R., Shuyu E., et al. Congenital hydrocephalus associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 cell lineages. Hum Mol Genet 2009, 18:142-150.
78. DiFiglia M., Sapp E., Chase K., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
79. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
80. DiFiglia M., Sena-Esteves M., Chase K., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007, 104:17204-17209.
81. Dion V., Lin Y., Price B.A., et al. Genome-wide demethylation promotes triplet repeat instability independently of homologous recombination. DNA Repair (Amst) 2008, 7:313-320.
82. Dixon K.T., Cearley J.A., Hunter J.M., et al. Mouse Huntington's disease homolog mRNA levels: variation and allele effects. Gene Expr 2004, 11:221-231.
83. Dixon M.J., Lahue R.S. DNA elements important for CAG*CTG repeat thresholds in Saccharomyces cerevisiae. Nucleic Acids Res 2004, 32:1289-1297.
84. Djian P., Hancock J.M., Chana H.S. Codon repeats in genes associated with human diseases: fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration. Proc Natl Acad Sci U S A 1996, 93:417-421.
85. Djousse L., Knowlton B., Hayden M., et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A 2003, 119A:279-282.
86. Djousse L., Knowlton B., Hayden M.R., et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 2004, 5:109-114.
87. Doi H., Okamura K., Bauer P.O., et al. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem 2008, 283:6489-6500.
88. Dragatsis I., Efstratiadis A., Zeitlin S. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 1998, 125:1529-1539.
89. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000, 26:300-306.
90. Dragatsis I., Goldovitz D., Del Mar N., et al. CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis 2009, 33:315-330.
91. Dragileva E., Hendricks A., Teed A., et al. Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes. Neurobiol Dis 2009, 33:37-47.
92. Dragunow M., Faull R.L., Lawlor P., et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995, 6:1053-1057.
93. Dunah A.W., Jeong H., Griffin A., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
94. Dure L.S., Landwehrmeyer G.B., Golden J., et al. IT15 gene expression in fetal human brain. Brain Res 1994, 659:33-41.
95. Durr A., Stevanin G., Cancel G., et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996, 39:490-499.
96. Duyao M., Ambrose C., Myers R., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993, 4:387-392.
97. Duyao M.P., Taylor S.A., Buckler A.J., et al. A gene from chromosome 4p16.3 with similarity to a superfamily of transporter proteins. Hum Mol Genet 1993, 2:673-676.
98. Duyao M.P., Auerbach A.B., Ryan A., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
99. Dyer R.B., McMurray C.T. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 2001, 29:270-278.
100. Edwards A., Hammond H.A., Jin L., et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992, 12:241-253.
101. Ehrlich M.E., Conti L., Toselli M., et al. ST14A cells have properties of a medium-size spiny neuron. Exp Neurol 2001, 167:215-226.
102. Ehrnhoefer D.E., Duennwald M., Markovic P., et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006, 15:2743-2751.
103. Ellison D.W., Beal M.F., Mazurek M.F., et al. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain 1987, 110:1657-1673.
104. Emerich D.F., Winn S.R., Hantraye P.M., et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997, 386:395-399.
105. Faber P.W., Barnes G.T., Srinidhi J., et al. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 1998, 7:1463-1474.
106. Faber P.W., Alter J.R., MacDonald M.E., et al. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A 1999, 96:179-184.
107. Faber P.W., Voisine C., King D.C., et al. Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci U S A 2002, 99:17131-17136.
108. Farrer L.A., Cupples L.A., Wiater P., et al. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am J Hum Genet 1993, 53:125-130.
109. Feng Z., Jin S., Zupnick A., et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 2006, 25:1-7.
110. Ferrante R.J., Kowall N.W., Beal M.F., et al. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987, 46:12-27.
111. Ferrante R.J., Andreassen O.A., Dedeoglu A., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002, 22:1592-1599.
112. Fischbeck K.H., Souders D., La Spada A. A candidate gene for X-linked spinal muscular atrophy. Adv Neurol 1991, 56:209-213.
113. Flinn L., Bretaud S., Lo C., et al. Zebrafish as a new animal model for movement disorders. J Neurochem 2008, 106:1991-1997.
114. Franich N.R., Fitzsimons H.L., Fong D.M., et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 2008, 16:947-956.
115. Freudenreich C.H., Lahiri M. Structure-forming CAG/CTG repeat sequences are sensitive to breakage in the absence of Mrc1 checkpoint function and S-phase checkpoint signaling: implications for trinucleotide repeat expansion diseases. Cell Cycle 2004, 3:1370-1374.
116. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003, 348:1365-1375.
117. Frim D.M., Uhler T.A., Short M.P., et al. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. NeuroReport 1993, 4:367-370.
118. Frim D.M., Uhler T.A., Galpern W.R., et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 1994, 91:5104-5108.
119. Fujigasaki H., Martin J.J., De Deyn P.P., et al. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. Brain 2001, 124:1939-1947.
120. Fu Y.H., Pizzuti A., Fenwick R.G., et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992, 255:1256-1258.
121. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J Neurosci 2002, 22:4842-4849.
122. Gafni J., Hermel E., Young J.E., et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 2004, 279:20211-20220.
123. Gardian G., Browne S.E., Choi D.K., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005, 280:556-563.
124. Gauthier L.R., Charrin B.C., Borrell-Pages M., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
125. Gayan J., Brocklebank D., Andresen J.M., et al. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet Epidemiol 2008, 32:445-453.
126. Gellerich F.N., Gizatullina Z., Nguyen H.P., et al. Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats. J Biol Chem 2008, 283:30715-30724.
127. Gerber H.P., Seipel K., Georgiev O., et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 1994, 263:808-811.
128. Geschwind D.H., Perlman S., Figueroa C.P., et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 1997, 60:842-850.
129. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?. Genes Dev 2004, 18:2046-2059.
130. Giordano M., Ford L.M., Shipley M.T., et al. Neural grafts and pharmacological intervention in a model of Huntington's disease. Brain Res Bull 1990, 25:453-465.
131. Gissi C., Pesole G., Cattaneo E., et al. Huntingtin gene evolution in Chordata and its peculiar features in the ascidian Ciona genus. BMC Genomics 2006, 7:288.
132. Giunti P., Sweeney M.G., Harding A.E. Detection of the Machado-Joseph disease/spinocerebellar ataxia three trinucleotide repeat expansion in families with autosomal dominant motor disorders, including the Drew family of Walworth. Brain 1995, 118:1077-1085.
133. Giunti P., Stevanin G., Worth P.F., et al. Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation. Am J Hum Genet 1999, 64:1594-1603.
134. Goehler H., Lalowski M., Stelzl U., et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004, 15:853-865.
135. Goffredo D., Rigamonti D., Tartari M., et al. Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J Biol Chem 2002, 277:39594-39598.
136. Goldberg Y.P., Andrew S.E., Theilmann J., et al. Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. J Med Genet 1993, 30:987-990.
137. Goldberg Y.P., Rommens J.M., Andrew S.E., et al. Identification of an Alu retrotransposition event in close proximity to a strong candidate gene for Huntington's disease. Nature 1993, 362:370-373.
138. Goldberg Y.P., Kremer B., Andrew S.E., et al. Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nat Genet 1993, 5:174-179.
139. Goldberg Y.P., Nicholson D.W., Rasper D.M., et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996, 13:442-449.
140. Gonitel R., Moffitt H., Sathasivam K., et al. DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A 2008, 105:3467-3472.
141. Gostout B., Liu Q., Sommer S.S. "Cryptic" repeating triplets of purines and pyrimidines (cRRY(i)) are frequent and polymorphic: analysis of coding cRRY(i) in the proopiomelanocortin (POMC) and TATA-binding protein (TBP) genes. Am J Hum Genet 1993, 52:1182-1190.
142. Graham R.K., Slow E.J., Deng Y., et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis 2006, 21:444-455.
143. Graham R.K., Deng Y., Slow E.J., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
144. Greene J.G., Greenamyre J.T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 1995, 64:430-436.
145. Gu M., Gash M.T., Mann V.M., et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996, 39:385-389.
146. Gusella J.F., Wexler N.S., Conneally P.M., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238.
147. Gusella J.F., Tanzi R.E., Anderson M.A., et al. DNA markers for nervous system diseases. Science 1984, 225:1320-1326.
148. Gusella J.F., Tanzi R.E., Bader P.I., et al. Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature 1985, 318:75-78.
149. Gutekunst C.A., Levey A.I., Heilman C.J., et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 1995, 92:8710-8714.
150. Gutekunst C.A., Li S.H., Yi H., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999, 19:2522-2534.
151. Hackam A.S., Singaraja R., Wellington C.L., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998, 141:1097-1105.
152. Hantraye P., Riche D., Maziere M., et al. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 1990, 108:91-104.
153. Hantraye P., Riche D., Maziere M., et al. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci U S A 1992, 89:4187-4191.
154. Hattula K., Peranen J. FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis. Curr Biol 2000, 10:1603-1606.
155. Henshaw R., Jenkins B.G., Schulz J.B., et al. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 1994, 647:161-166.
156. Her L.S., Goldstein L.S. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 2008, 28:13662-13672.
157. Hermel E., Gafni J., Propp S.S., et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 2004, 11:424-438.
158. Hersch S.M., Gevorkian S., Marder K., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
159. Hilditch-Maguire P., Trettel F., Passani L.A., et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000, 9:2789-2797.
160. Hockly E., Richon V.M., Woodman B., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003, 100:2041-2046.
161. Hodges A., Strand A.D., Aragaki A.K., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15:965-977.
162. Hodgson J.G., Smith D.J., McCutcheon K., et al. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum Mol Genet 1996, 5:1875-1885.
163. Hodgson J.G., Agopyan N., Gutekunst C.A., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
164. Hoffner G., Kahlem P., Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci 2002, 115:941-948.
165. Hohjoh H., Akari H., Fujiwara Y., et al. Molecular cloning and characterization of the common marmoset huntingtin gene. Gene 2009, 432:60-66.
166. Holbert S., Denghien I., Kiechle T., et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A 2001, 98:1811-1816.
167. Holbert S., Dedeoglu A., Humbert S., et al. Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Proc Natl Acad Sci U S A 2003, 100:2712-2717.
168. Holzmann C., Maueler W., Petersohn D., et al. Isolation and characterization of the rat huntingtin promoter. Biochem J 1998, 336:227-234.
169. Holzmann C., Schmidt T., Thiel G., et al. Functional characterization of the human Huntington's disease gene promoter. Brain Res Mol Brain Res 2001, 92:85-97.
170. Hoogeveen A.T., Willemsen R., Meyer N., et al. Characterization and localization of the Huntington disease gene product. Hum Mol Genet 1993, 2:2069-2073.
171. Horn S.C., Lalowski M., Goehler H., et al. Huntingtin interacts with the receptor sorting family protein GASP2. J Neural Transm 2006, 113:1081-1090.
172. Huang C.C., Faber P.W., Persichetti F., et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 1998, 24:217-233.
173. Huang K., Yanai A., Kang R., et al. Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron 2004, 44:977-986.
174. Humbert S., Bryson E.A., Cordelieres F.P., et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002, 2:831-837.
175. Hunter J.M., Lesort M., Johnson G.V. Ubiquitin-proteasome system alterations in a striatal cell model of huntington's disease. J Neurosci Res 2007, 85:1774-1788.
176. Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
177. Huntington Study Group Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003, 61:1551-1556.
178. Huntington G. On chorea. Med Surg Rep 1872, 26:320-321.
179. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
180. Ide K., Nukina N., Masuda N., et al. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem Biophys Res Commun 1995, 209:1119-1125.
181. Igarashi S., Morita H., Bennett K.M., et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 2003, 14:565-568.
182. Ikeda Y., Daughters R.S., Ranum L.P. Bidirectional expression of the SCA8 expansion mutation: One mutation, two genes. Cerebellum 2008, 7:150-158.
183. Imbert G., Saudou F., Yvert G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996, 14:285-291.
184. Isacson O., Riche D., Hantraye P., et al. A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen. Exp Brain Res 1989, 75:213-220.
185. Ishiguro H., Yamada K., Sawada H., et al. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene. J Neurosci Res 2001, 65:289-297.
186. Ishikawa K., Tanaka H., Saito M., et al. Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. Am J Hum Genet 1997, 61:336-346.
187. Jackson G.R., Salecker I., Dong X., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
188. Jana N.R., Nukina N. BAG-1 associates with the polyglutamine-expanded huntingtin aggregates. Neurosci Lett 2005, 378:171-175.
189. Jana N.R., Tanaka M., Wang G., et al. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 2000, 9:2009-2018.
190. Jana N.R., Zemskov E.A., Wang G., et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001, 10:1049-1059.
191. Jana N.R., Dikshit P., Goswami A., et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 2005, 280:11635-11640.
192. Jeong H., Then F., Melia T.J., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
193. Jou Y.S., Myers R.M. Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum Mol Genet 1995, 4:465-469.
194. Kahlem P., Djian P. The expanded CAG repeat associated with juvenile Huntington disease shows a common origin of most or all neurons and glia in human cerebrum. Neurosci Lett 2000, 286:203-207.
195. Kalchman M.A., Graham R.K., Xia G., et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996, 271:19385-19394.
196. Kalchman M.A., Koide H.B., McCutcheon K., et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 1997, 16:44-53.
197. Kaltenbach L.S., Romero E., Becklin R.R., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007, 3:e82.
198. Kang R., Wan J., Arstikaitis P., et al. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 2008, 456:904-909.
199. Kantor O., Temel Y., Holzmann C., et al. Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiol Dis 2006, 22:538-547.
200. Karlovich C.A., John R.M., Ramirez L., et al. Characterization of the Huntington's disease (HD) gene homologue in the zebrafish Danio rerio. Gene 1998, 217:117-125.
201. Kauffman J.S., Zinovyeva A., Yagi K., et al. Neural expression of the Huntington's disease gene as a chordate evolutionary novelty. J Exp Zoolog B Mol Dev Evol 2003, 297:57-64.
202. Kawaguchi Y., Okamoto T., Taniwaki M., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994, 8:221-228.
203. Kazantsev A., Walker H.A., Slepko N., et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 2002, 30:367-376.
204. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
205. Kegel K.B., Kim M., Sapp E., et al. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 2000, 20:7268-7278.
206. Kegel K.B., Meloni A.R., Yi Y., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 2002, 277:7466-7476.
207. Kells A.P., Fong D.M., Dragunow M., et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004, 9:682-688.
208. Kennedy L., Shelbourne P.F. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?. Hum Mol Genet 2000, 9:2539-2544.
209. Kennedy L., Evans E., Chen C.M., et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 2003, 12:3359-3367.
210. Kenney C., Powell S., Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord 2007, 22:127-130.
211. Kim M., Velier J., Chase K., et al. Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. Neuroscience 1999, 89:1159-1167.
212. Kim M., Lee H.S., LaForet G., et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999, 19:964-973.
213. Kim M., Roh J.K., Yoon B.W., et al. Huntingtin is degraded to small fragments by calpain after ischemic injury. Exp Neurol 2003, 183:109-115.
214. Kim M.O., Chawla P., Overland R.P., et al. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J Neurosci 2008, 28:3947-3957.
215. Kim Y.J., Yi Y., Sapp E., et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A 2001, 98:12784-12789.
216. Kim Y.J., Sapp E., Cuiffo B.G., et al. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol Dis 2006, 22:346-356.
217. Koide R., Ikeuchi T., Onodera O., et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994, 6:9-13.
218. Koide R., Kobayashi S., Shimohata T., et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?. Hum Mol Genet 1999, 8:2047-2053.
219. Koob M.D., Moseley M.L., Schut L.J., et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet 1999, 21:379-384.
220. Koroshetz W.J., Jenkins B.G., Rosen B.R., et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997, 41:160-165.
221. Kosinski C.M., Cha J.H., Young A.B., et al. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp Neurol 1997, 144:239-247.
222. Kovtun I.V., McMurray C.T. Features of trinucleotide repeat instability in vivo. Cell Res 2008, 18:198-213.
223. Kovtun I.V., Goellner G., McMurray C.T. Structural features of trinucleotide repeats associated with DNA expansion. Biochem Cell Biol 2001, 79:325-336.
224. Kremer B., Goldberg P., Andrew S.E., et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994, 330:1401-1406.
225. Krobitsch S., Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A 2000, 97:1589-1594.
226. Kuhl D.E., Markham C.H., Metter E.J., et al. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res Publ Assoc Res Nerv Ment Dis 1985, 63:199-209.
227. Kuhn A., Goldstein D.R., Hodges A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007, 16:1845-1861.
228. Laccone F., Engel U., Holinski-Feder E., et al. DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland. Neurology 1999, 53:801-806.
229. Laforet G.A., Sapp E., Chase K., et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001, 21:9112-9123.
230. Landwehrmeyer G.B., McNeil S.M., Dure L.S., et al. Huntington's Disease Gene: Regional and cellular expression in brain of normal and affected individuals. Ann Neurol 1995, 37:218-230.
231. La Spada A.R., Wilson E.M., Lubahn D.B., et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
232. La Spada A.R., Roling D.B., Harding A.E., et al. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet 1992, 2:301-304.
233. Leavitt B.R., Guttman J.A., Hodgson J.G., et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001, 68:313-324.
234. Lee J., Park E.H., Couture G., et al. An upstream open reading frame impedes translation of the huntingtin gene. Nucleic Acids Res 2002, 30:5110-5119.
235. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
236. Li H., Li S.H., Johnston H., et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 2000, 25:385-389.
237. Li J.L., Hayden M.R., Almqvist E.W., et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet 2003, 73:682-687.
238. Li S.H., Schilling G., Young W.S., et al. Huntington's Disease Gene (IT15) is widely expressed in human and rat tissues. Neuron 1993, 11:985-993.
239. Li S.H., Gutekunst C.A., Hersch S.M., et al. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998, 18:1261-1269.
240. Li S.H., Hosseini S.H., Gutekunst C.A., et al. A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. J Biol Chem 1998, 273:19220-19227.
241. Li S.H., Cheng A.L., Li H., et al. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J Neurosci 1999, 19:5159-5172.
242. Li Z., Karlovich C.A., Fish M.P., et al. A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet 1999, 8:1807-1815.
243. Li S.H., Cheng A.L., Zhou H., et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 2002, 22:1277-1287.
244. Li X.J., Li S.H., Sharp A.H., et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995, 378:398-402.
245. Li W., Serpell L.C., Carter W.J., et al. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J Biol Chem 2006, 281:15916-15922.
246. Lin B., Rommens J.M., Graham R.K., et al. Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Hum Mol Genet 1993, 2:1541-1545.
247. Lin B., Nasir J., MacDonald H., et al. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected]. Hum Mol Genet 1994, 3:85-92.
248. Lin B., Nasir J., Kalchman M.A., et al. Structural analysis of the 5' region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics 1995, 25:707-715.
249. Lin C.H., Tallaksen-Greene S., Chien W.M., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10:137-144.
250. Lin C.S., Altherr M., Bates G., et al. New DNA markers in the Huntington's disease gene candidate region. Somat Cell Mol Genet 1991, 17:481-488.
251. Lin Y., Hubert L., Wilson J.H. Transcription destabilizes triplet repeats. Mol Carcinog 2008, 48:350-361.
252. Liu B., Shuai K. Regulation of the sumoylation system in gene expression. Curr Opin Cell Biol 2008, 20:288-293.
253. Liu Y.F., Deth R.C., Devys D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 1997, 272:8121-8124.
254. Liu Y.F., Dorow D., Marshall J. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. J Biol Chem 2000, 275:19035-19040.
255. Lloret A., Dragileva E., Teed A., et al. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet 2006, 15:2015-2024.
256. Lopes-Cendes I., Teive H.G., Calcagnotto M.E., et al. Frequency of the different mutations causing spinocerebellar ataxia (SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients. Arq Neuropsiquiatr 1997, 55:519-529.
257. Lucotte G., Gerard N., Aouizerate A., et al. Patterns of meiotic variability of the (CAG)n repeat in the Huntington disease gene. Genet Couns 1997, 8:77-81.
258. Lumsden A.L., Henshall T.L., Dayan S., et al. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 2007, 16:1905-1920.
259. Lunkes A., Mandel J.L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998, 7:1355-1361.
260. Lunkes A., Trottier Y., Mandel J.L. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem 1998, 33:149-163.
261. Lunkes A., Lindenberg K.S., Ben-Haiem L., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 2002, 10:259-269.
262. Luo S., Rubinsztein D.C. Huntingtin promotes cell survival by preventing Pak2 cleavage. J Cell Sci 2009, 122:875-885.
263. Luo S., Vacher C., Davies J.E., et al. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 2005, 169:647-656.
264. Luo S., Mizuta H., Rubinsztein D.C. p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity. Hum Mol Genet 2008, 17:895-905.
265. Luthi-Carter R., Strand A., Peters N.L., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000, 9:1259-1271.
266. MacDonald M.E. Huntingtin: alive and well and working in middle management. Sci STKE 2003, pe48.
267. MacDonald M.E., Novelletto A., Lin C., et al. The Huntington's disease candidate region exhibits many different haplotypes. Nat Genet 1992, 1:99-103.
268. MacDonald M.E., Barnes G., Srinidhi J., et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet 1993, 30:982-986.
269. MacMillan J.C., Snell R.G., Tyler A., et al. Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet 1993, 342:954-958.
270. Maglione V., Cannella M., Gradini R., et al. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mech Ageing Dev 2006, 127:213-216.
271. Mahadevan M., Tsilfidis C., Sabourin L., et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255:1253-1255.
272. Majumder P., Raychaudhuri S., Chattopadhyay B., et al. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell Mol Neurobiol 2007, 27:1127-1145.
273. Mangiarini L., Sathasivam K., Seller M., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
274. Mangiarini L., Sathasivam K., Mahal A., et al. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet 1997, 15:197-200.
275. Manley K., Pugh J., Messer A. Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. Brain Res 1999, 835:74-79.
276. Manley K., Shirley T.L., Flaherty L., et al. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet 1999, 23:471-473.
277. Mann V.M., Cooper J.M., Javoy-Agid F., et al. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990, 336:749.
278. Mantle D., Falkous G., Ishiura S., et al. Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. J Neurol Sci 1995, 131:65-70.
279. Manto M.U. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 2005, 4:2-6.
280. Mao Z., Choo Y.S., Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 2006, 23:1701-1710.
281. Marcora E., Gowan K., Lee J.E. Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2. Proc Natl Acad Sci U S A 2003, 100:9578-9583.
282. Margolis R.L., Holmes S.E., Rosenblatt A., et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004, 56:670-674.
283. Mariotti C., Gellera C., Grisoli M., et al. Pathogenic effect of an intermediate-size SCA-6 allele (CAG)(19) in a homozygous patient. Neurology 2001, 57:1502-1504.
284. Marsh J.L., Walker H., Theisen H., et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000, 9:13-25.
285. Martin-Aparicio E., Avila J., Lucas J.J. Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci 2002, 16:355-359.
286. Martindale D., Hackam A., Wieczorek A., et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998, 18:150-154.
287. Martinez-Serrano A., Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 1996, 16:4604-4616.
288. Matsuyama N., Hadano S., Onoe K., et al. Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat. Genomics 2000, 69:72-85.
289. Matsuyama Z., Kawakami H., Maruyama H., et al. Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6). Hum Mol Genet 1997, 6:1283-1287.
290. Matthews R.T., Yang L., Jenkins B.G., et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998, 18:156-163.
291. Mazziotta J.C., Phelps M.E., Pahl J.J., et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987, 316:357-362.
292. McCampbell A., Taye A.A., Whitty L., et al. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci U S A 2001, 98:15179-15184.
293. McKeown C., Read A.P., Dodge A., et al. Wolf-Hirschhorn locus is distal to D4S10 on short arm of chromosome 4. J Med Genet 1987, 24:410-412.
294. Menalled L.B., Sison J.D., Wu Y., et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 2002, 22:8266-8276.
295. Menalled L.B., Sison J.D., Dragatsis I., et al. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003, 465:11-26.
296. Mende-Mueller L.M., Toneff T., Hwang S.R., et al. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J Neurosci 2001, 21:1830-1837.
297. Meriin A.B., Zhang X., He X., et al. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 2002, 157:997-1004.
298. Metzger S., Bauer P., Tomiuk J., et al. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. Hum Genet 2006, 120:285-292.
299. Metzger S., Bauer P., Tomiuk J., et al. The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 2006, 7:27-30.
300. Metzger S., Rong J., Nguyen H.P., et al. Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum Mol Genet 2008, 17:1137-1146.
301. Metzler M., Helgason C.D., Dragatsis I., et al. Huntingtin is required for normal hematopoiesis. Hum Mol Genet 2000, 9:387-394.
302. Miller V.M., Nelson R.F., Gouvion C.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 2005, 25:9152-9161.
303. Mishra A., Dikshit P., Purkayastha S., et al. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J Biol Chem 2008, 283:7648-7656.
304. Mitchell P.J., Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989, 245:371-378.
305. Modregger J., DiProspero N.A., Charles V., et al. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet 2002, 11:2547-2558.
306. Modregger J., Schmidt A.A., Ritter B., et al. Characterization of Endophilin B1b, a brain-specific membrane-associated lysophosphatidic acid acyl transferase with properties distinct from endophilin A1. J Biol Chem 2003, 278:4160-4167.
307. Morfini G.A., You Y.M., Pollema S.L., et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci 2009, 12:864-871.
308. Mormone E., Matarrese P., Tinari A., et al. Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. J Neurochem 2006, 98:1090-1099.
309. Morton A.J., Glynn D., Leavens W., et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 2009, 33:331-341.
310. Moseley M.L., Zu T., Ikeda Y., et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006, 38:758-769.
311. Muchowski P.J., Ning K., D'Souza-Schorey C., et al. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A 2002, 99:727-732.
312. Mugat B., Parmentier M.L., Bonneaud N., et al. Protective role of Engrailed in a Drosophila model of Huntington's disease. Hum Mol Genet 2008, 17:3601-3616.
313. Muller S., Ledl A., Schmidt D. SUMO: a regulator of gene expression and genome integrity. Oncogene 2004, 23:1998-2008.
314. Myers R.H. Huntington's disease genetics. NeuroRx 2004, 1:255-262.
315. Myers R.H., Leavitt J., Farrer L.A., et al. Homozygote for Huntington disease. Am J Hum Genet 1989, 45:615-618.
316. Nagafuchi S., Yanagisawa H., Ohsaki E., et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 1994, 8:177-182.
317. Nagafuchi S., Yanagisawa H., Sato K., et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994, 6:14-18.
318. Nakamura K., Jeong S.Y., Uchihara T., et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001, 10:1441-1448.
319. Namura S., Hirt L., Wheeler V.C., et al. The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia. Neurobiol Dis 2002, 11:147-154.
320. Nasir J., Floresco S.B., O'Kusky J.R., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823.
321. Neuwald A.F., Hirano T. HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. Genome Res 2000, 10:1445-1452.
322. Nguyen H.P., Kobbe P., Rahne H., et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet 2006, 15:3177-3194.
323. Nguyen H.P., Metzger S., Holzmann C., et al. Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics--Clinical Application 2008, 2:1638-1650.
324. Nucifora F.C., Sasaki M., Peters M.F., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
325. Obrietan K., Hoyt K.R. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J Neurosci 2004, 24:791-796.
326. O'Kusky J.R., Nasir J., Cicchetti F., et al. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Res 1999, 818:468-479.
327. Olsen J.V., Blagoev B., Gnad F., et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127:635-648.
328. Ona V.O., Li M., Vonsattel J.P., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
329. Oravecz-Wilson K.I., Kiel M.J., Li L., et al. Huntingtin Interacting Protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts. Hum Mol Genet 2004, 13:851-867.
330. Orr H.T., Chung M.Y., Banfi S., et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993, 4:221-226.
331. Osler W. Historical note on hereditary chorea. Neurographs 1908, 1:113-116.
332. Palfi S., Brouillet E., Jarraya B., et al. Expression of mutated Huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther 2007, 15:1444-1451.
333. Panov A.V., Gutekunst C.A., Leavitt B.R., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736.
334. Panov A.V., Lund S., Greenamyre J.T. Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem 2005, 269:143-152.
335. Pardo R., Colin E., Regulier E., et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 2006, 26:1635-1645.
336. Parker W.D., Boyson S.J., Luder A.S., et al. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990, 40:1231-1234.
337. Peel A.L., Rao R.V., Cottrell B.A., et al. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet 2001, 10:1531-1538.
338. Perez-Navarro E., Arenas E., Reiriz J., et al. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience 1996, 75:345-352.
339. Persichetti F., Srinidhi J., Kanaley L., et al. Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Dis 1994, 1:159-166.
340. Persichetti F., Ambrose C.M., Ge P., et al. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol Med 1995, 1:374-383.
341. Persichetti F., Carlee L., Faber P.W., et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis 1996, 3:183-190.
342. Perutz M.F., Johnson T., Suzuki M., et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 1994, 91:5355-5358.
343. Peters M.F., Ross C.A. Isolation of a 40-kDa Huntingtin-associated protein. J Biol Chem 2001, 276:3188-3194.
344. Petrasch-Parwez E., Nguyen H.P., Lobbecke-Schumacher M., et al. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 2007, 501:716-730.
345. Poirier M.A., Jiang H., Ross C.A. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 2005, 14:765-774.
346. Portera-Cailliau C., Hedreen J.C., Price D.L., et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995, 15:3775-3787.
347. Pratt G., Rechsteiner M. Proteasomes cleave at multiple sites within polyglutamine tracts: activation by PA28gamma(K188E). J Biol Chem 2008, 283:12919-12925.
348. Pribill I., Barnes G.T., Chen J., et al. Exon trapping and sequence-based methods of gene finding in transcript mapping of human 4p16.3. Somat Cell Mol Genet 1997, 23:413-427.
349. Pulst S.M., Nechiporuk A., Nechiporuk T., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996, 14:269-276.
350. Qi M.L., Tagawa K., Enokido Y., et al. Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 2007, 9:402-414.
351. Qin Z.H., Wang Y., Kegel K.B., et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 2003, 12:3231-3244.
352. Rangone H., Poizat G., Troncoso J., et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004, 19:273-279.
353. Ratovitski T., Nakamura M., D'Ambola J., et al. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 2007, 6:2970-2981.
354. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107-1117.
355. Ravikumar B., Stewart A., Kita H., et al. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum Mol Genet 2003, 12:985-994.
356. Raychaudhuri S., Sinha M., Mukhopadhyay D., et al. HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity. Hum Mol Genet 2008, 17:240-255.
357. Reddy P.H., Williams M., Charles V., et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998, 20:198-202.
358. Reddy P.H., Charles V., Williams M., et al. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999, 354:1035-1045.
359. Regulier E., Trottier Y., Perrin V., et al. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum Mol Genet 2003, 12:2827-2836.
360. Riess O., Schols L., Bottger H., et al. SCA6 is caused by moderate CAG expansion in the alpha1A-voltage-dependent calcium channel gene. Hum Mol Genet 1997, 6:1289-1293.
361. Riess O., Laccone F.A., Gispert S., et al. SCA2 trinucleotide expansion in German SCA patients. Neurogenetics 1997, 1:59-64.
362. Rigamonti D., Bauer J.H., De-Fraja C., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000, 20:3705-3713.
363. Rockabrand E., Slepko N., Pantalone A., et al. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007, 16:61-77.
364. Rubinsztein D.C., Leggo J., Coles R., et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996, 59:16-22.
365. Rudnicki D.D., Pletnikova O., Vonsattel J.P., et al. A comparison of huntington disease and huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008, 67:366-374.
366. Runne H., Regulier E., Kuhn A., et al. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci 2008, 28:9723-9731.
367. Sadri-Vakili G., Cha J.H. Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2006, 2:330-338.
368. Sadri-Vakili G., Menon A.S., Farrell L.A., et al. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. Eur J Neurosci 2006, 23:3171-3175.
369. Sadri-Vakili G., Bouzou B., Benn C.L., et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007, 16:1293-1306.
370. Sanchez I., Xu C.J., Juo P., et al. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
371. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
372. Sanpei K., Takano H., Igarashi S., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996, 14:277-284.
373. Sapp E., Schwarz C., Chase K., et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997, 42:604-612.
374. Saudou F., Finkbeiner S., Devys D., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
375. Savas J.N., Makusky A., Ottosen S., et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci U S A 2008, 105:10820-10825.
376. Schaffar G., Breuer P., Boteva R., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004, 15:95-105.
377. Schapira A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1999, 1410:159-170.
378. Schiffer N.W., Broadley S.A., Hirschberger T., et al. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J Biol Chem 2007, 282:9195-9203.
379. Schilling B., Gafni J., Torcassi C., et al. Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 2006, 281:23686-23697.
380. Schilling G., Sharp A.H., Loev S.J., et al. Expression of the Huntington's disease (IT15) protein product in HD patients. Hum Mol Genet 1995, 4:1365-1371.
381. Schilling G., Becher M.W., Sharp A.H., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999, 8:397-407.
382. Schilling G., Coonfield M.L., Ross C.A., et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 2001, 315:149-153.
383. Schilling G., Savonenko A.V., Klevytska A., et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum Mol Genet 2004, 13:1599-1610.
384. Schmitt I., Bachner D., Megow D., et al. Expression of the Huntington disease gene in rodents: cloning the rat homologue and evidence for downregulation in non-neuronal tissues during development. Hum Mol Genet 1995, 4:1173-1182.
385. Schols L., Vieira-Saecker A.M., Schols S., et al. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. Hum Mol Genet 1995, 4:1001-1005.
386. Schols L., Kruger R., Amoiridis G., et al. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998, 64:67-73.
387. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
388. Semaka A., Creighton S., Warby S., et al. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 2006, 70:283-294.
389. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004, 56:319-328.
390. Seong I.S., Ivanova E., Lee J.M., et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005, 14:2871-2880.
391. Sharp A.H., Loev S.J., Schilling G., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995, 14:1065-1074.
392. Shelbourne P.F., Killeen N., Hevner R.F., et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999, 8:763-774.
393. Shelbourne P.F., Keller-McGandy C., Bi W.L., et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet 2007, 16:1133-1142.
394. Shibata M., Lu T., Furuya T., et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem 2006, 281:14474-14485.
395. Sieradzan K.A., Mechan A.O., Jones L., et al. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999, 156:92-99.
396. Sinadinos C., Burbidge-King T., Soh D., et al. Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol Dis 2009, 34:389-395.
397. Singaraja R.R., Hadano S., Metzler M., et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 2002, 11:2815-2828.
398. Sipione S., Rigamonti D., Valenza M., et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 2002, 11:1953-1965.
399. Sittler A., Walter S., Wedemeyer N., et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 1998, 2:427-436.
400. Slow E.J., van Raamsdonk J., Rogers D., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
401. Snell R.G., Thompson L.M., Tagle D.A., et al. A recombination event that redefines the Huntington disease region. Am J Hum Genet 1992, 51:357-362.
402. Solans A., Zambrano A., Rodriguez M., et al. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet 2006, 15:3063-3081.
403. Song C., Perides G., Liu Y.F. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 2002, 277:6703-6707.
404. Squitieri F., Gellera C., Cannella M., et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003, 126:946-955.
405. Stack E.C., Del Signore S.J., Luthi-Carter R., et al. Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 2007, 16:1164-1175.
406. Steffan J.S., Kazantsev A., Spasic-Boskovic O., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000, 97:6763-6768.
407. Steffan J.S., Bodai L., Pallos J., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
408. Steffan J.S., Agrawal N., Pallos J., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
409. Stelzl U., Worm U., Lalowski M., et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005, 122:957-968.
410. Stevanin G., Giunti P., Belal G.D., et al. De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Hum Mol Genet 1998, 7:1809-1813.
411. Stevanin G., Fujigasaki H., Lebre A.S., et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003, 126:1599-1603.
412. Stine O.C., Pleasant N., Franz M.L., et al. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 1993, 2:1547-1549.
413. Stine O.C., Li S.H., Pleasant N., et al. Expression of the mutant allele of IT-15 (the HD gene) in striatum and cortex of Huntington's disease patients. Hum Mol Genet 1995, 4:15-18.
414. Strand A.D., Aragaki A.K., Shaw D., et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005, 14:1863-1876.
415. Strong T.V., Tagle D.A., Valdes J.M., et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993, 5:259-265.
416. Sugars K.L., Brown R., Cook L.J., et al. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 2004, 279:4988-4999.
417. Suhr S.T., Senut M.C., Whitelegge J.P., et al. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 2001, 153:283-294.
418. Sun B., Fan W., Balciunas A., et al. Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol Dis 2002, 11:111-122.
419. Sun Y., Savanenin A., Reddy P.H., et al. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J Biol Chem 2001, 276:24713-24718.
420. Suopanki J., Gotz C., Lutsch G., et al. Interaction of huntingtin fragments with brain membranes - clues to early dysfunction in Huntington's disease. J Neurochem 2006, 96:870-884.
421. Susel Z., Engber T.M., Kuo S., et al. Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease. Neurosci Lett 1991, 121:234-238.
422. Tai H.C., Schuman E.M. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008, 9:826-838.
423. Takano H., Gusella J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci 2002, 3:15.
424. Takiyama Y., Igarashi S., Rogaeva E.A., et al. Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet 1995, 4:1137-1146.
425. Takiyama Y., Sakoe K., Namekawa M., et al. A Japanese family with spinocerebellar ataxia type 6 which includes three individuals homozygous for an expanded CAG repeat in the SCA6/CACNL1A4 gene. J Neurol Sci 1998, 158:141-147.
426. Tanaka K., Shouguchi-Miyata J., Miyamoto N., et al. Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington's disease gene. J Biol Chem 2004, 279:7275-7286.
427. Tanaka Y., Igarashi S., Nakamura M., et al. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 2006, 21:381-391.
428. Tang T.S., Tu H., Chan E.Y., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
429. Tartari M., Gissi C., Lo Sardo V., et al. Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 2008, 25:330-338.
430. Taylor S.A., Barnes G.T., MacDonald M.E., et al. A dinucleotide repeat polymorphism at the D4S127 locus. Hum Mol Genet 1992, 1:142.
431. Taylor S.A.M., Snell R.G., Buckler A., et al. Cloning of the α-adducin gene from the Huntington's disease candidate region of chromosome 4 by exon amplification. Nat Genet 1992, 2:223-227.
432. Telenius H., Kremer H.P., Theilmann J., et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 1993, 2:1535-1540.
433. Telenius H., Kremer B., Goldberg Y.P., et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet 1994, 6:409-414.
434. Telenius H., Almqvist E., Kremer B., et al. Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease. Hum Mol Genet 1995, 4:189-195.
435. Temel Y., Cao C., Vlamings R., et al. Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease. Neurosci Lett 2006, 406:138-141.
436. Thakur A.K., Wetzel R. Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A 2002, 99:17014-17019.
437. Trettel F., Rigamonti D., Hilditch-Maguire P., et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000, 9:2799-2809.
438. Trottier Y., Biancalana V., Mandel J.L. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet 1994, 31:377-382.
439. Trottier Y., Devys D., Imbert G., et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995, 10:104-110.
440. Trottier Y., Lutz Y., Stevanin G., et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995, 378:403-406.
441. Truant R., Atwal R.S., Desmond C., et al. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. Febs J 2008, 275:4252-4262.
442. Trushina E., Singh R.D., Dyer R.B., et al. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 2006, 15:3578-3591.
443. Tukamoto T., Nukina N., Ide K., et al. Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Brain Res Mol Brain Res 1997, 51:8-14.
444. Uchida M., Shimatsu Y., Onoe K., et al. Production of transgenic miniature pigs by pronuclear microinjection. Transgenic Res 2001, 10:577-582.
445. Usdin M.T., Shelbourne P.F., Myers R.M., et al. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 1999, 8:839-846.
446. Van Raamsdonk J.M., Metzler M., Slow E., et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 2007, 26:189-200.
447. Varani K., Abbracchio M.P., Cannella M., et al. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. Faseb J 2003, 17:2148-2150.
448. Velier J., Kim M., Schwarz C., et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol 1998, 152:34-40.
449. Venkatraman P., Wetzel R., Tanaka M., et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004, 14:95-104.
450. Verbessem P., Lemiere J., Eijnde B.O., et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003, 61:925-930.
451. Verkerk A.J., Pieretti M., Sutcliffe J.S., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
452. Vetter I.R., Arndt A., Kutay U., et al. Structural view of the Ran-Importin beta interaction at 2.3 A resolution. Cell 1999, 97:635-646.
453. von Horsten S., Schmitt I., Nguyen H.P., et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003, 12:617-624.
454. Vonsattel J.P. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115:55-69.
455. Wang J., Wang C.E., Orr A., et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 2008, 180:1177-1189.
456. Wanker E.E., Rovira C., Scherzinger E., et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997, 6:487-495.
457. Warby S.C., Chan E.Y., Metzler M., et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 2005, 14:1569-1577.
458. Warby S.C., Doty C.N., Graham R.K., et al. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 2008, 40:121-127.
459. Warby S.C., Doty C.N., Graham R.K., et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 2008, 17:2390-2404.
460. Watanabe M., Satoh A., Kanemoto M., et al. De novo expansion of a CAG repeat in a Japanese patient with sporadic Huntington's disease. J Neurol Sci 2000, 178:159-162.
461. Wellington C.L., Brinkman R.R., O'Kusky J.R., et al. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol 1997, 7:979-1002.
462. Wellington C.L., Ellerby L.M., Hackam A.S., et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998, 273:9158-9167.
463. Wellington C.L., Singaraja R., Ellerby L., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 2000, 275:19831-19838.
464. Wellington C.L., Ellerby L.M., Gutekunst C.A., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 2002, 22:7862-7872.
465. Westhoff B., Chapple J.P., van der Spuy J., et al. HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome. Curr Biol 2005, 15:1058-1064.
466. Wexler N.S., Conneally P.M., Housman D., et al. A DNA polymorphism for Huntington's disease marks the future. Arch Neurol 1985, 42:20-24.
467. Weydt P., Pineda V.V., Torrence A.E., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006, 4:349-362.
468. Weydt P., Soyal S.M., Gellera C., et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009, 4:3.
469. Wheeler V.C., Auerbach W., White J.K., et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 1999, 8:115-122.
470. Wheeler V.C., White J.K., Gutekunst C.A., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000, 9:503-513.
471. Wheeler V.C., Lebel L.A., Vrbanac V., et al. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet 2003, 12:273-281.
472. White J.K., Auerbach W., Duyao M.P., et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997, 17:404-410.
473. Williams J.K., Schutte D.L. Genetic testing and mental health: the model of Huntington disease. Online J Issues Nurs 2000, 5:3.
474. Winborn B.J., Travis S.M., Todi S.V., et al. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 2008, 283:26436-26443.
475. Wullner U., Young A.B., Penney J.B., et al. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994, 63:1772-1781.
476. Wyttenbach A., Swartz J., Kita H., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 2001, 10:1829-1845.
477. Xia J., Lee D.H., Taylor J., et al. Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 2003, 12:1393-1403.
478. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
479. Yanai A., Huang K., Kang R., et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 2006, 9:824-831.
480. Yang H., Zhong X., Ballar P., et al. Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp Cell Res 2007, 313:538-550.
481. Yang S.H., Cheng P.H., Banta H., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453:921-924.
482. Yohrling G.J., Cha J.H. Neurochemistry of Huntington's disease. Huntington's Disease 2002, 276-308. Oxford Medical Publications, London. 3rd Edn. G.P. Bates, P.S. Harper, A.L. Jones (Eds.).
483. Yohrling G.J., Farrell L.A., Hollenberg A.N., et al. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol Cell Neurosci 2003, 23:28-38.
484. Young A.B., Penney J.B., Starosta-Rubinstein S., et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986, 20:296-303.
485. Zala D., Colin E., Rangone H., et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008, 17:3837-3846.
486. Zeitlin S., Liu J.P., Chapman D.L., et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995, 11:155-163.
487. Zhang H., Das S., Li Q.Z., et al. Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci 2008, 9:38.
488. Zhang X., Smith D.L., Meriin A.B., et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005, 102:892-897.
489. Zhou H., Cao F., Wang Z., et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 2003, 163:109-118.
490. Zhuchenko O., Bailey J., Bonnen P., et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997, 15:62-69.
491. Zhu J., He F., Hu S., et al. On the nature of human housekeeping genes. Trends Genet 2008, 24:481-484.
492. Zuccato C., Ciammola A., Rigamonti D., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
493. Zuccato C., Tartari M., Crotti A., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003, 35:76-83.
494. Zuhlke C., Hellenbroich Y., Dalski A., et al. Different types of repeat expansion in the TATA-binding protein gene are associated with a new form of inherited ataxia. Eur J Hum Genet 2001, 9:160-164.
495. Zuhlke C., Dalski A., Hellenbroich Y., et al. Spinocerebellar ataxia type 1 (SCA1): phenotype-genotype correlation studies in intermediate alleles. Eur J Hum Genet 2002, 10:204-209.
496. Zuhlke C., Gehlken U., Hellenbroich Y., et al. Phenotypical variability of expanded alleles in the TATA-binding protein gene. Reduced penetrance in SCA17?. J Neurol 2003, 250:161-163.